Metabolic Research Stack

£57.99

Purity: ≥ 99%

£57.99

Metabolic Research Stack

Name: Metabolic Research Stack
Brand: Pure Grade Labs
Price: 57.99 GBP
Availability: OutOfStock

£57.99

Purity: ≥ 99%

£57.99

VISCERAL FAT - Visceral adipose tissue reduction and abdominal fat research

LIPOLYSIS - GH-dependent and independent fat oxidation pathway research

METABOLIC SAFETY - IGF-1 feedback preservation and glycaemic safety research

BODY COMPOSITION - Visceral fat reduction with lean mass preservation research

Two Mechanisms. One Target: Visceral Adipose Tissue.

The Metabolic Research Stack combines AOD-9604 and Tesamorelin - two compounds that both demonstrate effects on visceral fat in research, but through fundamentally different mechanisms. AOD-9604 is a modified HGH C-terminal fragment that acts via beta-3 adrenergic receptor stimulation and lipogenesis inhibition, independent of the growth hormone axis. Tesamorelin is an FDA-approved GHRH analogue that stimulates endogenous GH secretion, which in turn drives GH-mediated visceral lipolysis through IGF-1 and GH receptor pathways.

What makes this combination scientifically distinct is that it addresses visceral adipose tissue from two independent entry points simultaneously: one circumventing the GH axis entirely, one working through it. Tesamorelin is one of the most clinically documented peptides in this class - it has completed Phase III human trials (n=806) and received FDA approval as Egrifta® for visceral fat reduction in HIV-associated lipodystrophy, providing a human evidence base that most research peptides cannot claim.

AOD-9604

Modified HGH C-terminal analogue (aa 177-191, N-terminal Tyr addition). Developed at Monash University to isolate lipolytic activity from growth-promoting HGH effects. Research has documented beta-3 adrenergic receptor activation, lipogenesis inhibition, and absence of IGF-1 or insulin elevation. Completed Phase IIb human trials. FDA GRAS status granted for food use. Mechanism operates independently of the GH/IGF-1 axis.

Tesamorelin

Synthetic GHRH analogue with trans-3-hexenoyl group at the N-terminus, protecting it from DPP-4 cleavage and extending stability relative to native GHRH. Developed by Theratechnologies Inc. FDA-approved as Egrifta®. Phase III trials (n=806) documented 15-20% reductions in visceral adipose tissue by CT imaging at 26 weeks. Acts via the GHRH receptor on anterior pituitary somatotrophs to stimulate physiological, pulsatile GH release - preserving the IGF-1 negative feedback loop absent in exogenous GH administration.

AOD-9604 Sequence (Modified HGH C-Terminal): Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-NH2

Tesamorelin Sequence (Modified GHRH 1-44): Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

AOD-9604 MW: 1,818.1 g/mol

Tesamorelin MW: 5,135.9 g/mol

AOD-9604 CAS: 221231-10-3

Tesamorelin CAS: 218949-48-5

2010 | Journal of Clinical Endocrinology & Metabolism | Phase III Human Trial (Pooled, n=806)

Tesamorelin reduces visceral adipose tissue by 15-20% over 26 weeks in a pooled Phase III analysis

Falutz et al. published a pooled analysis of two multicenter, international Phase III trials enrolling 806 ART-treated HIV patients with excess abdominal fat, randomised 2:1 to tesamorelin 2mg or placebo subcutaneously daily. CT-measured visceral adipose tissue decreased by a mean of 15-20% in treated subjects at 26 weeks compared to placebo. Subcutaneous adipose tissue was largely preserved, demonstrating visceral selectivity. Importantly, glucose parameters including fasting glucose, 2-hour OGTT, and HbA1c were not significantly different between groups at 26 weeks, directly addressing concerns about GH-related insulin resistance. The authors concluded that tesamorelin reduces VAT and maintains the reduction for up to 52 weeks without clinically meaningful metabolic adverse effects.

Falutz J, et al. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PubMed →

2017 | PLOS One | Phase II RCT / Human

Tesamorelin maintains glycaemic safety in type 2 diabetes: 12-week randomised controlled trial

A randomised, double-blind, placebo-controlled 12-week trial examined tesamorelin's metabolic safety profile in patients with type 2 diabetes. No significant differences were observed between groups in relative insulin response, fasting glucose, HbA1c, or overall diabetes control at Week 12. The authors attributed glycaemic safety to the preserved IGF-1 negative feedback on GH secretion that GHRH analogues maintain - a mechanistic advantage over exogenous GH administration, where feedback is bypassed. This study provided important evidence that GHRH analogue-induced GH elevation does not carry the insulin-sensitising liability of direct GH injection in a diabetic population.

Clemmons DR, et al. PLoS One. 2017;12(6):e0179538. PubMed →

2001 | Journal of Endocrinology | Animal Study

AOD-9604 reduces adiposity without affecting IGF-1 or insulin in rodent obesity models

Heffernan et al. investigated AOD-9604 and full-length HGH in diet-induced and genetic mouse obesity models. AOD-9604 produced significant reductions in adipose tissue mass and body weight at doses substantially lower than those required for full HGH to produce equivalent lipolytic effects. Critically, AOD-9604 did not elevate IGF-1 or insulin levels, and did not produce the insulin resistance observed with full HGH treatment. The authors concluded that the C-terminal fragment retained the lipolytic activity of HGH while dissociating it from growth-promoting and diabetogenic effects - confirming the GH-axis-independent mechanism that distinguishes AOD-9604 from Tesamorelin in terms of pathway utilised.

Heffernan M, et al. J Endocrinol. 2001;168(1):R1-R6. PubMed →

2019 | Journal of Clinical Endocrinology & Metabolism | Human Study

Tesamorelin increases skeletal muscle area in subjects with significant visceral fat reduction

Srinivasa et al. analysed the body composition effects of tesamorelin beyond VAT reduction. Among subjects achieving clinically significant decreases in visceral adipose tissue on treatment, tesamorelin was effective in increasing skeletal muscle area and density as measured by CT. The study documented that the GH-mediated anabolic effects on lean tissue - a downstream consequence of IGF-1 elevation driven by GHRH stimulation - were preserved alongside the lipolytic effects on visceral fat. This provides a mechanistic rationale for the body composition profile observed: simultaneous VAT reduction and lean mass preservation that is distinct from caloric restriction or direct lipolytic approaches alone.

Srinivasa S, et al. J Clin Endocrinol Metab. 2019;104(8):3253-3260. PubMed →

Every Metabolic Research Stack ships with a batch-specific Certificate of Analysis from an independent third-party analytical laboratory, covering both AOD-9604 and Tesamorelin vials. The COA confirms identity, purity by HPLC, and absence of contaminants.

Both compounds are supplied as lyophilised (freeze-dried) solids. Bacteriostatic water is required for reconstitution and is available separately. Storage specifications below apply to both vials.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction. Bacteriostatic water is supplied ready to use - no preparation required.
Use the included bacteriostatic water as reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously. Both compounds dissolve readily in BAC water.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

AOD-9604 and Tesamorelin supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human use by any regulatory authority unless specifically noted.

Tesamorelin is FDA-approved as Egrifta® for HIV-associated lipodystrophy only. This supply is for research use and does not constitute the approved pharmaceutical product.
AOD-9604 holds FDA GRAS status for food use and completed Phase IIb trials. Neither designation constitutes approval for injectable or therapeutic use.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy beyond what is described in the cited research literature.
Both compounds are prohibited in sport by WADA. Athletes subject to drug testing should be aware of applicable classifications.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations on this page are provided for informational context only and do not constitute medical advice or recommendation for human use.